LCD L36159: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — Noridian
Policy LCD-L36159 · Hematology
New genetic testing guidelines for thrombophilia impact billing.
Code intelligence
I82.90 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code I82.90.
Elevated code riskView ICD-10 detail
Signal breakdown
6 shown · 6 total in platform
Risk: Elevated
0
Critical
0%
5
High
83%
1
Routine
17%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L36155: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — Noridian
Policy LCD-L36155 · Hematology
New LCD for genetic testing could impact billing processes.
Proposed LCD DL40242: MolDX: Genetic Testing for Hereditary Thrombophilia — Noridian
Policy LCD-DL40242 · Hematology
New LCD for hereditary thrombophilia testing impacts billing.
Proposed LCD DL40259: MolDX: Genetic Testing for Hereditary Thrombophilia — CGS
Policy LCD-DL40259 · Hematology
Impact on genetic testing billing for thrombophilia.
LCD L35998: Non-Coronary Vascular Stents — WPS
Policy LCD-L35998 · Cardiology
New billing guidelines for non-coronary vascular stents.
Proposed LCD DL40276: Non-invasive Arterial Duplex Ultrasound of the Upper and Lower Extremities — Novitas
Policy LCD-DL40276 · Radiology
New LCD requires billing team review.
Audit documentation
Building an audit file that includes I82.90?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Hematology audit pack — $349One-time purchase · not a subscription